Hybrid APC Therapy in Early Central Lung Neoplasms

NACompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

December 26, 2018

Primary Completion Date

February 22, 2022

Study Completion Date

December 30, 2023

Conditions
Lung Neoplasms
Interventions
PROCEDURE

Hybrid APC

• HybridAPC is integrated with traditional APC and water-jet technique, which has been successfully applied for endoscopic treatment of mucosal lesions in GI, such as Barrett esophageal and lesions in colon. Submucosal injection of water jet can elevate superficial lesion, and then APC can be more effective in ablation of superficial tumor with a protection for muscular layer. The application of HybridAPC in respiratory intervention could theoretically protect cartilage, adventitia, reduce damage and formation of scare, and increase ablation energy to reach radical treatment. • High-frequency EBUS, could display the boundary between cartilage endomembrane and cartilage, in order to determine the depth of tumor.

Trial Locations (1)

200030

Shanghai Chest Hospital, Shanghai

All Listed Sponsors
collaborator

Shanghai Pulmonary Hospital, Shanghai, China

OTHER

collaborator

The First Affiliated Hospital of Guangzhou Medical University

OTHER

lead

Jiayuan Sun

OTHER

NCT03537378 - Hybrid APC Therapy in Early Central Lung Neoplasms | Biotech Hunter | Biotech Hunter